# Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-08 03:29 UTC · Category: Business · Sources: 5 · Current Velocity: 2.8

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| marketscreener.com | Novo Nordisk Phase 3 Trial Meets Primary Endpoint for Child Obesity Drug | 2026-09-07 12:39 | [Source Link](https://news.google.com/rss/articles/CBMiwwFBVV95cUxQM09PNWcwU2FDNjlYRFdFVlBEakwtR2VuYnJHVW1iMkRuRGRyT1pkc0o1WjVQc0RyZi1GSGpOOTJ5aEliNkptdmoydmkyYWY4ZUQyMERkTlI2LXFBLW54STRCa1hxMWY4V3dlU3Y2cVRoRzlrODQ1MGZxN2xqelNPQWpvSVJDaEZxenlwbUlIZmNlaXhrZnpjMVNqWnVCbktSYUJ4Vlppc2VCOHlScVRFaVp4cDBvLWNDRUFwYXltRXhUdlk?oc=5) |
| pharma.economictimes.indiatimes.com | Novo scraps two more heart drug trials, further dimming growth beyond obesity | 2026-09-07 12:39 | [Source Link](https://news.google.com/rss/articles/CBMi5gFBVV95cUxPUi1MUU5CWm9sOXdlMGJBR1JQLXQtRlVQQ1h5OUQ0TXB6M2tnenhIdGtWU3dlN2F5OVdERXg4ZjdlWWtGUmdVc0d3WkU3YVhSMDlqNUtqSnVoMmtnRnFTMF9aQ1NnNEkySVFFTE9FT3IzaEpXMU1VSjlQblg3LVJVdXpXdlg0X1lBNk8xTHpRU3FwQndzTzViQUZheVBXdkdwOGpjNXZsVE4xNlZlbDFOQ19WcFhkRmcyQU1sdmRQOWNvYmF2ZU5rUVVQSjlPNDhsTlpvTklyS1FmZV8tSGFURTIzM0hlZ9IB6wFBVV95cUxQT01oMERPdm5Fb2I2czdfTzI4MjFhMWdUdktGd3ZYZzlrNWs5cHRIS0x1ZUFsbDVEX2duTmtya1V0alJEcTlQcmU1ZFMwb2oyVVVwdUFucnNNY2dQOFVSbW9vNElxN1kyOEhKVzQ) |
| Barron's | GLP1 Drugs Work for Kids, Says Novo Nordisk. They Could Be Another Huge Market. | 2026-09-07 12:39 | [Source Link](https://news.google.com/rss/articles/CBMid0FVX3lxTE9FRERIUFRzQ3dBRFlnT0J4Mk45Nm5zQmo4aVdSQ19UUV9obGhCTEtJWGRlTlMxNi0taHVYTktKRWRoVFpaWjNZV1FHV2VZRGNaSTRrbGIxS2l5SHNEQm1LOHVXZno5U0M0eUJaSkM1R3JUemRNTy1z?oc=5) |
| Fierce Pharma | Novo Nordisk’s Wegovy helps free 40% of kids from obesity in phase 3 trial | 2026-09-07 12:39 | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxOUEJvNm9OU2ZTQ015ZVY5cTlWNUlobVhnaVVCUUNPTzlTZkhvSUR6eko4dXp4bENFaFpSczZkY2FlcGVjMkFZcXo3dUU5dmJXZHF5UWFkTkFaYmlsa2NmXzhzRDBER2lteE1URXA4Zks2Zk9GSkd1VmNpdGJOVmE2aUM3alBRYWQxQ295c0IzdHBHdjhvRzNrZTgtWTB1QQ?oc=5) |
| Clinical Trials Arena | Novo Nordisk’s ziltivekimab stumbles again on pair of Phase III terminations | 2026-09-07 12:39 | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxQejhfUVlmV2VjQnlXQXpPeUN6SlBNc0M2NVhBWm83NXBfOUc1R0FRWmV1NW16T1ZMUlpWa25hR3NZVUtqUVVCbTUzTmZCV2FaY29ZNnV4cGhGUXc5VWk1WnR2RGM0TG5VSHRkeXl6WmktSG55eDVqVlc0YS1Qc0luWG9jb3N3alRHcTBZcW5xMnlvSXo2?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-08/novo-s-blockbuster-hopes-for-ckd-program-dwindle-after-more-phase-3-trials*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*